Covid-19 roundup: Sinopharm touts 'better than expected' PhIII vaccine data; After Pfizer/BioNTech, Russia claims vaccine is 92% effective on slimmer evidence
On the heels of groundbreaking Covid-19 vaccine data from Pfizer and BioNTech — and Russia’s claims that its Sputnik V is just as good — China’s Sinopharm said late-stage data from its candidates are “better than expected.”
It’s unclear what Sinopharm is basing its characterization on. In a statement posted on WeChat, the state-owned company noted that its trials are in final stages, with over 50,000 volunteers enrolled in the United Arab Emirates, Bahrain, Egypt, Jordan, Morocco, Peru, Argentina and others.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.